Stay updated with breaking news from Felix Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Claire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.
A biologics license application seeking the approval of obecabtagene autoleucel for the treatment of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.
Dr Short discusses data in acute lymphoblastic leukemia that were presented at the 2023 ASCO Annual Meeting and EHA Congress.
Claire Roddie, MD, discusses the rationale for investigating obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, details the key topline findings from the FELIX trial, and provides insights on unmet needs that remain for this patient population.
Claire Roddie, MD, discusses the patient population and topline efficacy findings from the phase 1/2 FELIX trial, which is investigating the CD19-directed CAR T-cell therapy obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.